BioAtla, Inc.

NASDAQ:BCAB

2.09 (USD) • At close November 1, 2024
Bedrijfsnaam BioAtla, Inc.
Symbool BCAB
Munteenheid USD
Prijs 2.09
Beurswaarde 101,021,613
Dividendpercentage 0%
52-weken bereik 1.14 - 4.02
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jay M. Short Ph.D.
Website https://www.bioatla.com

An error occurred while fetching data.

Over BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It

Vergelijkbare Aandelen

Eton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc.

ETON

8.62 USD

Akumin Inc. logo

Akumin Inc.

AKU

0.289 USD

Vigil Neuroscience, Inc. logo

Vigil Neuroscience, Inc.

VIGL

3.87 USD

Wave Life Sciences Ltd. logo

Wave Life Sciences Ltd.

WVE

13.83 USD

SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc.

SABS

3.88 USD

Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc.

ASMB

16.89 USD

Lipocine Inc. logo

Lipocine Inc.

LPCN

6.08 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)